363 / 1311
CTV L4-L3: 1-3 N+: INDICATIONS
Randomized trials are PENDING:
RTOG 9915 (SWOG)
EORTC (SUPREMO – Selective Use of Postoperative Radiotherapy After Mastectomy): In
this trial, apart from randomize 1-3 N(+) patients, pT2 pN0 with grade 3 and/or
vasculo-lymphatic invasion are also randomized.
NCI CTG
French study
↓
11.5%
↓
7.9%
EBCTG META-ANALYSIS: POSITIVE RESULTS OF SURVIVAL 1-3 N+